Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum by Gatton, M. L. et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2004, p. 2116–2123 Vol. 48, No. 6
0066-4804/04/$08.000 DOI: 10.1128/AAC.48.6.2116–2123.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Evolution of Resistance to Sulfadoxine-Pyrimethamine in
Plasmodium falciparum
Michelle L. Gatton,1,2* Laura B Martin,1,2† and Qin Cheng3
Malaria and Scabies Group, Queensland Institute of Medical Research, Royal Brisbane Hospital,
Brisbane, Queensland 4029,1 Australian Centre for International and Tropical Health and
Nutrition, University of Queensland, Queensland 4072,2 and Department of Drug
Resistance and Diagnostics, Australian Army Malaria Institute,
Gallipoli Barracks, Enoggera, Queensland
4051,3 Australia
Received 27 October 2003/Returned for modification 22 December 2003/Accepted 5 February 2004
The development of resistance to sulfadoxine-pyrimethamine by Plasmodium parasites is a major problem
for the effective treatment of malaria, especially P. falciparum malaria. Although the molecular basis for
parasite resistance is known, the factors promoting the development and transmission of these resistant
parasites are less clear. This paper reports the results of a quantitative comparison of factors previously
hypothesized as important for the development of drug resistance, drug dosage, time of treatment, and drug
elimination half-life, with an in-host dynamics model of P. falciparum malaria in a malaria-naïve host. The
results indicate that the development of drug resistance can be categorized into three stages. The first is the
selection of existing parasites with genetic mutations in the dihydrofolate reductase or dihydropteroate
synthetase gene. This selection is driven by the long half-life of the sulfadoxine-pyrimethamine combination.
The second stage involves the selection of parasites with allelic types of higher resistance within the host during
an infection. The timing of treatment relative to initiation of a specific anti-P. falciparum EMP1 immune
response is an important factor during this stage, as is the treatment dosage. During the third stage, clinical
treatment failure becomes prevalent as the parasites develop sufficient resistance mutations to survive ther-
apeutic doses of the drug combination. Therefore, the model output reaffirms the importance of correct
treatment of confirmed malaria cases in slowing the development of parasite resistance to
sulfadoxine-pyrimethamine.
Drug resistance is becoming an increasingly important factor
in the effective treatment of malaria. High levels of resistance
to chloroquine have forced some countries to switch their
first-line drug to sulfadoxine-pyrimethamine (SP, trade name
Fansidar). However, resistance to this drug combination is
developing fast, with treatment failure being reported in Af-
rica, Asia, Indonesia, and South America (5, 7, 16, 20, 31).
Pyrimethamine and sulfadoxine act synergistically to inhibit
two enzymes important in the parasite’s folate biosynthetic
pathway, dihydrofolate reductase (DHFR) and dihydro-
pteroate synthetase (DHPS) (13). Point mutations in the
DHFR and DHPS genes confer resistance to pyrimethamine
and sulfadoxine, respectively, with decreasing in vitro Plasmo-
dium falciparum susceptibility related to the number of muta-
tions in each gene (6, 30, 34). The same mutations have been
linked to treatment failure in the clinical setting (5, 7, 20, 33);
the presence of mutations in DHFR appear to be more impor-
tant in causing treatment failure than DHPS mutations (5).
Although the molecular basis for SP resistance is understood,
the factors promoting the development and transmission of
these mutants are less clear.
It has been suggested that drug pharmacokinetics (12),
overusage of drugs (28), cross-resistance between drugs (14),
and inadequate treatment through inappropriate prescription
or administration, noncompliance, or poor absorption (28, 36)
contribute to the development of resistance. The timing of
treatment relative to the initiation of an immune response in
the patient has also been hypothesized as important in devel-
oping resistance (10), as have host immunity and transmission
level (13, 38). Although individual factors involved in the evo-
lution of drug resistance have been identified, the relative
importance of these factors has not been reported in a quan-
titative format. This paper considers the influence of drug
dosage and the timing of treatment on the rate of SP treatment
failure predicted by a simulation model of P. falciparum infec-
tion. It also quantifies the relative importance of these factors
in the development of SP resistance resulting in treatment
failure. The selective pressure exerted by the long half-life of
SP is also considered relative to its role in promoting the
development and spread of resistance.
MATERIALS AND METHODS
A previously reported in-host dynamics model (9) was used to simulate a P.
falciparum infection in a malaria-naive human host. Simulations were conducted
with the model parameter set obtained from fitting the model to data from
patients infected with the El Limon and Santee Cooper P. falciparum parasite
strains (9). This parameter set was used because it had previously been validated
against various clinical outcomes (9). Parasite mutation was assumed to be a
stochastic event occurring in either the DHFR or DHPS gene or both at a rate
of 109 mutations/gene/replication (25). Drug treatment was included in the
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model by reducing the parasite load in accordance with the drug dosage and time
since treatment. A Poisson distribution with mean Pi  Tm,j was used to estimate
the number of surviving parasites, where Pi is the number of parasites in the host
on day i and Tm,j is the probability of a parasite’s surviving the effect of drug
dosage j, m days posttreatment.
The probability of parasites’ surviving at various time points after treatment
was determined by combining information from SP isobolograms (32) and dose-
response curves (39). Isobolograms for parasites containing triple mutations
(3M) in both the DHFR and DHPS genes (3M/3M) and for parasites containing
a triple mutation in DHFR and the wild-type DHPS gene (3M/WT) were digi-
tized. These isobolograms contain the 50% inhibitory concentration (IC50) val-
ues for various SP concentrations in the presence of 45 nM folic acid. To estimate
the probability of parasites’ surviving, the dose-response curve for py-
rimethamine (24) was used to estimate scaling factors, from which an IC50 in the
isobolograms could be converted to an ICx (where x  0, . . ., 100). The results
from three dose-response curves, two from wild-type parasites (24, 39) and one
from parasites containing a single mutation in DHFR (24), were averaged to
achieve the scaling factors. It was assumed that these scaling factors were also
applicable to sulfadoxine.
To calculate the survival probabilities for mutation combinations other than
3M/3M and 3M/WT, the following were assumed: a single mutation at codon 108
in the DHFR gene results in a 50-fold increase in the IC50 relative to the
wild-type parasite (3, 5, 6, 25, 26); a double mutation in DHFR results in a
170-fold increase in the IC50 relative to the wild type (4, 6, 22, 26); a triple
mutation in the DHFR gene results in a 700-fold increase in the IC50 compared
to the wild type (3, 6); and single, double, and triple mutations in DHPS result
in 15-, 45-, and 800-fold increases relative to the wild type in the IC50 for
sulfadoxine, respectively (22, 34). These values were used to scale the isobolo-
grams to represent other DHFR-DHPS mutation combinations.
Plasma drug concentrations were estimated by assuming that the average
maximum concentration of pyrimethamine and sulfadoxine in the plasma of an
adult after a standard three-tablet dose of Fansidar (75 mg of pyrimethamine and
1,500 mg of sulfadoxine) is 2.58 M and 612 M, respectively (35). Between 80
and 90% of pyrimethamine and 90 and 95% of sulfadoxine bind to plasma
proteins (17), leaving approximately 0.52 and 60 M unbound pyrimethamine
and sulfadoxine, respectively, to act on the parasites. The elimination half-life of
pyrimethamine and sulfadoxine was assumed to be 95.5 and 184 h, respectively
(35). With this information, the drug concentration at various time points fol-
lowing treatment was determined. Three treatment regimes were simulated: the
recommended three-tablet dose of Fansidar that reaches 100% of the expected
plasma concentration, the recommended three-tablet dose of Fansidar that
reaches 80% of the expected plasma concentration (e.g., poor absorption of
drug), and a two-tablet dose of Fansidar. Figure 1 illustrates how the parasite
genotype and drug kinetics were combined to estimate the probability of para-
sites’ surviving drug treatment.
To assess the selective pressure exerted by the long elimination half-life of SP,
simulations were conducted to mimic individuals with and without residual drug
in the blood (treated and untreated populations, respectively). Residual drug
concentrations were tracked for 48 days following treatment. After this time
period, it was assumed that the drug concentration had no effect on the parasites
and that the status of an individual converted to untreated. It was also assumed
that individuals in the treated population received a three-tablet (100% effective)
SP dose that cured the initial infection and that the threshold for activation of the
nonspecific immune response was higher for subsequent infections than for the
initial infection (8). As the probability of receiving an infectious bite during the
48 days following treatment is dependent on the transmission intensity in the
area, the methodology outlined in the Appendix was used to estimate the ratio
of treated to untreated individuals for a given transmission intensity.
RESULTS
SP treatment failure rates were calculated for 144 different
scenarios (three treatment regimes  three treatment times 
16 DHFR-DHPS mutation combinations), with 1,000 simula-
tions of the model run for each scenario. Treatment times were
selected to encompass the various states of the anti-Plasmo-
dium falciparum EMP1 immune response (Table 1). Treat-
ment failure was defined as incomplete clearance (elimination)
of parasites from the host.
The treatment failure rates predicted from the model are
displayed in Fig. 2 for the various treatment and genotype
combinations. As expected, the failure rate was zero for infec-
tions with wild-type parasites and those with minimal muta-
tions, increasing to 100% as the number of mutations in DHFR
and DHPS increased. Mutations in the DHFR gene were more
influential on treatment failure than mutations in DHPS. For
the double mutation (2M) DHFR/WT DHPS genotype (2M/
WT), neither the time of treatment during the infection nor
the dose had any noticeable effect on the failure rate. However,
combining treatment at day 8 with suboptimal dosing resulted
in high levels of treatment failure. Beginning with the 2M/WT
genotype, the addition of one extra mutation in DHPS was
FIG. 1. Parasite survival in the presence of various SP concentra-
tions. (A) The wild-type (WT/WT) and (B) the 3M DHFR/3M DHPS
parasite genotypes. Symbols on each of the surfaces indicate the SP
concentrations that can be expected within a host 0, 12, 24, 36, and 48
days following treatment with a standard three-tablet dose of SP.
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sufficient to cause a dramatic increase in treatment failure if
treatment was administered on day 8, irrespective of the drug
dosage. High numbers of mutations in DHFR (e.g., 3M/WT)
were prone to significantly increased treatment failure rates if
SP was administered 8 days after the start of the asexual in-
fection or if a suboptimal treatment dosage was delivered.
Even at high levels of mutation, treatment was still effective for
approximately 13% of infections if the patient was dosed with
the recommended concentration of drug upon presentation
with symptoms. Overall, a trend toward the onset of treatment
failure occurred with fewer mutations when suboptimal SP
treatment was delivered. Irrespective of the drug dosage for
infections that failed treatment, the time interval between
treatment and the appearance of recrudescent parasites de-
creased with increasing levels of parasite mutation (data not
shown).
A feature common to all simulations was the development of
a subpopulation of parasites carrying mutations additional to
the parental population. In most simulations, this subpopula-
tion remained a negligible proportion of the total parasite
burden. However, when treatment was administered 8 days
after the start of the asexual infection, the subpopulation of
mutated parasites was occasionally selected within the host
(Table 2). The proportion of simulations in which this selection
occurred increased with increasing number of mutations in the
parental population and also with decreasing drug dosage.
The presence of residual drug in the blood protected indi-
viduals against reinfection for up to 26 days depending on the
genotype of the infecting parasite (Fig. 3). Various degrees of
protection against reinfection were provided for all genotypes
with the exception of 2M DHFR/2M DHPS and parasites con-
taining triple mutations in the DHFR gene (irrespective of the
DHPS genotype). Protection against reinfection for longer
than 14 days was only provided with wild-type parasites and
parasites having WT DHRF/1M, 2M, and 3M DHPS geno-
types. In most simulations, the onset of symptoms was delayed
when residual drug was present in the blood. The magnitude of
this delay decreased with increasing mutation level and/or time
since treatment (Fig. 3). However once infected, the overall
treatment failure rate for each of the DHFR-DHPS genotype
combinations simulated did not differ between cases with or
without residual drug in their blood.
As a consequence of the protection afforded by the residual
drug, a change in the prevalence of each parasite genotype
over time was noted; the prevalence of the wild-type and wild-
type DHFR/mutated DHPS parasites decreased with a corre-
sponding increase in the other genotype combinations. The
TABLE 1. Pathology of simulated P. falciparum infections caused by the El Limon and Santee Cooper parasite strains
treated at three different time points
Time of treatment
(days after start of
blood-stage
infection)
Avg parasitemia
(no./l) Simulated symptoms and host responses
a
8 250 Typically no fever; nonspecific immunity and specific immunity not yet triggered
10 2,700–3,000 Fever; antibodies to some dominant EMP1 variants triggered
12 3,000–5,500 Severe fever; antibodies to most (if not all) EMP1 variants expressed early in
the infection have been triggered
a EMP1, P. falciparum erythrocyte membrane protein 1.
FIG. 2. Predicted treatment failure rates for various parasite geno-
types when infections are treated with (A) three SP tablets, (B) three
SP tablets which achieve 80% of the expected plasma concentration,
and (C) two SP tablets. Genotypes not included in the graph had no
simulated treatment failures. Simulations were conducted with treat-
ment at 8 (solid bars), 10 (striped bars), or 12 days (open bars) after
the start of the blood-stage infection.
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rate of selection of the more mutated parasites depended on
the transmission rate of the region (Fig. 4). A high transmis-
sion rate appeared to accelerate the selection of mutated par-
asites.
Assessing the relative importance of various factors in the
development of drug resistance depended on the level of mu-
tation within the parasite population at any time. A schematic
diagram showing the fate of parasites following treatment with
SP indicates that there was no mechanism for individual wild-
type and singly mutated parasites to advance their mutation
level (Fig. 5). However, this group of parasites was subject to
strong negative selection pressure caused by the long elimina-
tion half-life of SP. In contrast, after parasites achieved a single
mutation in DHFR and a triple mutation in DHPS (1M/3M),
treatment 8 days after the start of the blood-stage infection
provided an environment in which parasites with additional
mutations had a selective advantage within the host. Since
there was no mechanism for flow of parasites between muta-
tion groups early in the development of resistance, the initial
presence of parasites with mutated DHFR and/or DHPS genes
was fundamental for drug resistance to develop. Given that
genetic mutation is a random occurrence, it would be expected
that some parasites harbor these mutations, even with very low
mutation rates and the absence of drug pressure.
DISCUSSION
The rapid development of parasite resistance to antimalaria
drugs is a fundamental problem for the effective treatment of
malaria. Understanding the factors promoting the develop-
ment of resistance is the first step to prolonging the effective
therapeutic life of a drug. Here we have presented a compar-
ative analysis of some factors previously implicated as impor-
tant in the development of resistance by analyzing sulfadoxine-
pyrimethamine treatment failure rates predicted by an in-host
dynamics model of P. falciparum malaria. The selection pres-
sure exerted by this long-acting drug combination on the dis-
tribution of parasite genotypes was also investigated.
The results presented need to be viewed relative to the
assumptions of the model. The first and probably most impor-
TABLE 2. Prevalence of recrudescent infections with 1% of
parasites carrying an additional mutation compared to the infecting
parasite and with treatment administered 8 days after the start of
asexual infection
DHFR/DHPS
genotype of
infecting
parasite
% of simulations with 1% of recrudescent parasites
carrying an extra mutation
Three tablets
achieving 100%
of expected
concn
Three tablets
achieving 80% of
expected concn
Two tablets
achieving 100%
of expected
concn
1M/3M 0.0a 0.0a 0.5a,b
2M/WT 0.0 0.3b 1.7
2M/1M 1.5 2.6 4.0
2M/2M 2.6 6.5 15.6
2M/3M 10.2a 18.6a 20.9a
a Additional mutations can only occur in the DHFR gene.
b All infections that recrudesced had 1% of parasites carrying an additional
mutation compared to the infecting parasite.
FIG. 3. Effect of residual drug on reinfection rates and develop-
ment of clinical malaria. The percentage of reinfections that were
successful by wild-type parasites (WT/WT) and parasites with a double
mutation in either the DHFR (2M/WT) or DHPS (WT/2M) gene
following SP treatment is indicated by the solid, dotted, and dashed
lines, respectively. The bars indicate the mean time until the appear-
ance of symptoms requiring treatment following reinfections occurring
between 2 and 32 days post-SP treatment.
FIG. 4. Illustrative changes in the prevalence of parasite genotypes
caused by SP use in (A) low-transmission regions (1.8 infectious
bites/year) and (B) high-transmission regions (18 infectious bites/
year). In each region, the ratio of genotypes prior to the introduction
of SP treatment was set to 9,900:30:30:10:10:10:7:3 for WT/WT, 1M/
WT, WT/1M, 1M/1M, 2M/WT, WT/2M, 2M/1M, and 2M/2M para-
sites, respectively. The 1M/1M genotype was omitted because its prev-
alence curve was indistinguishable from the curve of the WT/1M
genotype parasites.
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tant consideration is that the model mimics a P. falciparum
infection in a malaria-naïve host such as a child, visitor, or
immigrant from a nonmalarious area. Since semi-immune in-
dividuals typically respond better to treatment than hosts not
previously exposed to malaria (37), the model output would be
expected to overestimate the treatment failure rate for semi-
immune individuals. The second consideration relates to mod-
eling a single clone of parasites. In areas of high transmission,
multiple infections are likely; the model ignores the effect of
parasite recombination, which can act to reduce the probability
that resistance will be retained by the parasite (11). Lastly, the
determination of the speed with which resistance develops is
restricted to limited situations in which everyone within a pop-
ulation of malaria-naïve hosts is treated when they become
sick. This may occur in situations where a population is relo-
cated into a malarious area and closely monitored. In other
situations where only a proportion of the people are treated,
the selection pressure on parasites would be expected to be less
than that indicated. As such, the model predictions reported
here represent a worse-case scenario for a naïve population.
Since the identification of molecular markers for SP resis-
tance, numerous field studies have assessed the correlation
between genetic mutations and treatment failure. A number of
studies have attributed SP treatment failure to infection with
parasites having at least a double mutation in DHFR coupled
with a single mutation in the DHPS gene (1, 5, 7, 15, 20). The
model results presented here are in agreement with these find-
ings. A more detailed comparison of treatment failure rates for
specific parasite genotypes indicated that the model predic-
tions for mutation levels of 2M/1M or above encompass re-
ported treatment failure rates at 3 days and 7 days posttreat-
ment (4, 19). The simulation results also suggest that even
within a naïve host, processes such as antigenic variation and
the corresponding immune response that develops to it during
the course of an infection may play a role in reducing the
treatment failure rate. This type of interaction may explain the
apparent discrepancy between the proportion of parasite iso-
lates that are resistant in vitro and the much reduced incidence
of in vivo treatment failure (1).
The model’s prediction that treatment failure rates increase
with suboptimal dosing agrees with field data from Kenyan
children (29). The same study reported that treatment failure
rates were higher in individuals who had been treated with SP
in the 5 weeks prior to the current infection (29). Our predic-
tions suggest that the increase in treatment failure observed
may be due to the different length of protection afforded
against reinfection for different parasite genotypes, so that only
resistant parasites can reinfect individuals shortly after SP
treatment.
The model output indicates that for the parasite character-
istics considered, treatment of infections caused by parasites
having at least two mutations in DHFR prior to the triggering
of the specific immune response (day 8 in the model) resulted
in 100% treatment failure, whereas treatment after the stimu-
lation of the specific immune response (either day 10 or 12 in
the model) resulted in lower failure rates. This result appears
to contradict the general belief that treatment of an infection
at a smaller parasite burden (earlier time) reduces the chances
of treatment failure. However, closer examination of the fac-
tors influencing the survival of parasites following treatment
indicates that the infectious load is not the only factor perti-
nent to determining treatment failure. This is particularly true
for infections caused by parasites having at least two mutations
in DHFR, for which even optimal doses of SP are often not
sufficient to kill 100% of parasites. In these situations, the
parasite burden is severely reduced following treatment but
FIG. 5. Schematic illustration of the evolution of SP resistance. The fate of parasites following treatment with SP is indicated for each genotype.
At low levels of mutation, there is no mechanism for advancement of mutation level. However, the presence of residual drug concentrations
provides a strong selection pressure against the indicated genotypes (). At intermediate mutation levels, early suboptimal treatment provides an
environment where parasites with additional mutations may be selected for within the host, leading to treatment failure. At high mutation levels,
parasites are often able to survive therapeutic doses of SP, causing treatment failure.
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gradually increases again as the drug concentrations within the
host wane. This high treatment failure rate can be improved by
the development of a specific immune response to the variant
antigens that can mop up the parasites not killed by the drug
combination. Therefore, treating infections early so as to have
a smaller biomass is important for infections with parasites
having no or low levels of mutation but is predicted to lead to
increased treatment failure in infections caused by highly re-
sistant parasites.
For the parasite characteristics assumed in this model, the
specific immunity for most of the expressed var genes has been
triggered by day 12, coinciding with the onset of symptoms,
while no or few antibodies have been triggered by day 8. How-
ever, these values are an approximation only and may vary for
different parasites depending on the rate of var gene switching,
the number of parasites expressing a variant required to trigger
the specific immunity, and also the pyrogenic threshold (dic-
tating the onset of symptoms).
In the majority of simulations in which recrudescence oc-
curred, the model predicted that the recrudescent parasites
exhibited the same genotype as those in the initial infection.
However, parasites with additional mutations could become
prominent under certain circumstances. These results agree
with in vitro data showing no significant difference between the
mean IC50 values of pyrimethamine and sulfadoxine for paired
blood samples taken from patients prior to SP treatment and
from recrudescent infections post-SP treatment (18). Epidemi-
ological data collected from malaria-infected children also in-
dicated that in the majority of SP treatment failures, the re-
crudescent parasites had the same DHFR-DHPS genotype as
the parasites in the initial infection (23; A. Nzila, personal
communication).
Although the model is able to predict the frequency of par-
asites with additional mutations becoming dominant within a
host, it is not able to estimate the probability of these newly
developed parasites being transmitted through the mosquito to
a new human host and subsequently becoming successfully
established in a community. Recent reports demonstrate that
gene flow rather than new mutation is responsible for the high
level of resistance mutations in the parasite’s DHFR and
DHPS in Africa (27) and DHFR in southeast Asia (21). This
suggests that the successful establishment of these new mu-
tated parasites in the community is a rare event.
The model predicted that the long half-life of SP provides
strong selective pressure against parasites carrying wild-type
DHFR, potentially resulting in the rapid decline of the wild-
type DHFR genotype in high-transmission areas. Such a pro-
cess may account for the rapid decrease (from 18 to 4% in 12
months) in the prevalence of the wild-type DHFR genotype in
Tanzania (16). The model output also suggested that the in-
frequent observation of sulfadoxine-resistant but py-
rimethamine-sensitive parasites in the field (18) may result
from the greater selection pressure against wild-type DHFR/
mutant DHPS parasites compared to mutant DHFR/wild-type
DHPS parasites.
Although the long half-life of SP exerts a selection pressure
favoring mutated parasites, it also has the potential to reduce
the infection and transmission rate by providing some protec-
tion against reinfection. The actual magnitude of the potential
decrease in transmission rate is related to the prevalence of
parasites carrying mutations in DHFR and DHPS and the pro-
portion of the population receiving treatment and therefore
having residual drug in their blood. Such a decrease in trans-
mission rate could partially offset the selection pressure caused
by the long elimination half-life of SP. The current model,
which was designed to mimic the in-host dynamics of P. falci-
parum infections in a naïve individual, requires further devel-
opment to explore these types of interactions. Only then can
the overall impact of SP treatment within a human population
be assessed.
Hastings et al. (12) proposed that the evolution of drug
resistance could be split into two distinct phases: the transition
from wild-type parasites to slightly mutated forms that are less
sensitive to the drug, but are still killed by therapeutic concen-
trations and the conversion from low to high levels of mutation
and the emergence of clinical resistance to the drug. It was
hypothesized that the level of drug usage in the population was
a fundamental factor during the first stage, while the propor-
tion of infections treated within the population was the pri-
mary factor influencing the second stage in the evolution of
drug resistance (12). The results reported here support this
general hypothesis, but suggest that there is an additional in-
termediate stage in which suboptimal treatment of low-grade
infections is important.
The results presented indicate that the best protocol for
slowing the development of drug resistance to SP is optimal
treatment of individuals after the development of clinical
symptoms and subsequent confirmation of malaria. The pre-
sumptive treatment of malaria by health workers or through
self-medication has the potential to increase the speed with
which resistance develops for two reasons. First, presumptive
treatment of illnesses thought to be malaria creates a situation
in which a larger proportion of the population has drug in their
blood. This acts to increase the selection pressure against wild-
type parasites, although it may also result in a reduction in
transmission. Second, presumptive treatment of nonimmune
individuals who are not ill from malaria but do carry low-grade
resistant parasitemia due to a developing malaria infection
results in treatment being administered prior to the triggering
of any specific immune response. This has the potential to
cause treatment failure, possibly selecting for a more resistant
parasite population within the host.
The speed with which drug resistance develops is dictated by
the prevalence of parasites carrying mutations in DHFR and/or
DHPS when the drug is first introduced. Therefore, resistance
to SP would be expected to develop more rapidly in areas
where drugs targeting the same active site as either py-
rimethamine or sulfadoxine have been or are being used (2,
14). Although these drugs may not necessarily be used to treat
malaria, their use will ultimately result in malaria parasites’
being exposed to subtherapeutic doses, providing an environ-
ment promoting the development of resistance to a component
of the SP combination. Examples of this include the use of
sulfa drugs to treat bacterial infections (31) or the use of
trimethoprim, which cross-reacts with pyrimethamine, as a
prophylactic treatment for opportunistic infections in human
immunodeficiency virus-infected individuals (14). Since drug
resistance is a problem for many infectious diseases, a com-
bined effort from disease specialists is required to devise an
overall treatment strategy which best suits the needs of an
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individual country or region. In this way, the effective life of
many drugs used to treat multiple diseases may be extended.
The simulation model used in this analysis of SP resistance
is equally applicable to the investigation of the development of
drug resistance to other antimalarial combinations. A prime
candidate for such analysis is the chlorproguanil-dapsone com-
bination. With the pharmacokinetic data specific for this drug
combination, it would be interesting to speculate on the factors
promoting resistance and explore the likelihood of treatment
failure with chlorproguanil-dapsone in regions already experi-
encing SP failure. Such analysis would provide useful informa-
tion on the likely success and effective life of this new drug
combination.
APPENDIX
Assuming that people were treated when they had a nonspecific
immune response sufficient to cause a fever, the proportion of the
population who received an infectious bite that would result in a
blood-stage infection was calculated (equation 1). For the untreated
population, rk,i  1, while in the treated population, 0  rk,i  1,
depending on the drug concentration within the blood at the time of
infection,
Si b
k
pk rk, i 
j1
i1 1 b
k
pk rk, j (1)
where Si is the proportion of the population receiving an infectious bite
on day i which will eventuate in a developing blood-stage infection (i
 0, . . ., 48 and i  0 represents the day that the initial infection was
treated), b is the probability of receiving an infectious bite (per day), pk
is the proportion of parasites carrying DHFR/DHPS genotype k, and
rk,j is the probability of a blood-stage infection developing if infected
with parasites of DHFR-DHPS genotype k on day j. The proportion of
the population becoming infected and failing SP treatment within the
48-day period is defined as

i1
48 
k
pk rk, i fk (2)
where fk is the probability of treatment failure for infections with
parasites of genotype k.
Ignoring parasite recombination and assuming that every person
who becomes sick is treated and has an equal opportunity to transmit
parasites to a susceptible mosquito, the change in the prevalence of
genotypes can be tracked over time by using equation 3. The super-
scripts U and T represent the values of previously defined variables (S
and r) in the untreated and treated populations, respectively. A time
period representing 48 days is used in these calculations.
pk,q Vdk,q1
U  	1 V
dk,q1
T (3)
where pk,q is the proportion of parasites with genotype k at time period
q, V is the proportion of the population not treated with SP within the
last 48 days, and dUk,q1 is the proportion of untreated patients in-
fected with parasites of genotype k during the time period
	m 1
dk,q1U j1
48
pk b	1 b
	 j1


j1
48
Sj
U  (4)
and pTk,q1 is the proportion of treated patients infected with parasites
of genotype k during the time period
	m 1
pk,q1T j1
48 pkrk, jT b 
l1
j1 1 b
k
pkrk, l
T 

j1
48
Sj
T  (5)
If all individuals who become sick are treated, the ratio of untreated
to treated populations is
1
j1
48
Sj
T

j1
48
Sj
U
(6)
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